Assessing national cervical cancer screening guidelines: Results from an HIV testing clinic also screening for cervical cancer and HPV in Soweto, South Africa

被引:6
|
作者
Hopkins, Kathryn L. [1 ,2 ]
Jaffer, Maya [1 ]
Hlongwane, Khuthadzo E. [1 ]
Otwombe, Kennedy [1 ]
Dietrich, Janan [1 ,3 ]
Cheyip, Mireille [4 ]
Olivier, Jacobus [4 ]
Doherty, Tanya [2 ,3 ]
Gray, Glenda E. [1 ,5 ]
机构
[1] Univ Witwatersrand, Chris Hani Baragwanath Acad Hosp, Fac Hlth Sci, Perinatal HIV Res Unit, Johannesburg, South Africa
[2] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa
[3] South African Med Res Council, Hlth Syst Res Unit, Cape Town, South Africa
[4] Ctr Dis Control & Prevent, Pretoria, South Africa
[5] South African Med Res Council, Off President, Cape Town, South Africa
来源
PLOS ONE | 2021年 / 16卷 / 07期
基金
新加坡国家研究基金会;
关键词
PAPILLOMAVIRUS; PREVENTION; PREVALENCE; INFECTION; DISEASES; HISTORY; WOMEN;
D O I
10.1371/journal.pone.0255124
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective A screening centre in Soweto, South Africa (SA), investigated high-risk human papillomavirus (HR-HPV), HIV, cervical cancer risk amongst women. Methods This cross-sectional study (June 2018-March 2019) describes screening results (Roche Linear Array HPV test and Pap smear liquid based cytology) and history of screening (known HIV status, antiretroviral therapy [ART] use, previous Pap smears). Data were stratified by age group (18-29, 30+ years), HIV status, Pap smear results and tested for statistical significance. Results Of 280 women, 20.4% were HIV-positive, 18.2% had abnormal Pap smears, 41.8% had HR-HPV. Of older women, 48.2% (n = 78/162) had never had a Pap smear. Of younger women, 89.0% (n = 105/118) never had a Pap smear, but had significantly more low-grade squamous intraepithelial lesions (LSIL) and other HR-HPV infection than older women (12.7%[n = 15/118] vs 4.9%[n = 8/162], p = 0.0193; and 49.2%[n = 58/118] vs 29.0%[n = 47/162], p = 0.0006; respectively). HIV-positive women had more abnormal cytology results and infection with other HR-HPV types or co-infection with other HR-HPV type(s)/HPV-16 compared to HIV-negative women (35.1%[n = 20/57] vs 13.9%[n = 31/223], p = 0.0002; 56.1%[n = 32/57] vs 32.7%[n = 73/223], p = 0.001; and 12.3%[n = 7/57] vs 4.9%[n = 11/223], p = 0.044; respectively). Of 57 HIV-positive women, 45.6% (n = 26) already knew their HIV status; of which 69.2% were on ART and 34.6% never had a Pap smear. Conclusion South African women have high rates of HIV, Pap smear abnormalities and HR-HPV, with low cervical cancer screening coverage. SA cervical cancer screening policy excludes (undiagnosed) HIV-positive and HIV-negative women <30 years, both populations found to have high prevalence of HR-HPV. HPV-based primary screening from 25 years could improve outcomes.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Guidelines for HPV-DNA Testing for Cervical Cancer Screening in Brazil
    Zeferino, Luiz Carlos
    Bastos, Joana Braganca
    Andrade Peixoto do Vale, Diama Bhadra
    Zanine, Rita Maria
    Mendes Furtado de Melo, Yara Lucia
    Salles Pereira Primo, Walquiria Quida
    Correa, Flavia de Miranda
    Chulvis do Val, Isabel Cristina
    Russomano, Fabio
    [J]. REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2018, 40 (06): : 360 - 368
  • [2] 2012 Cervical Cancer Screening Guidelines and the Future Role of HPV Testing
    Priebe, Anna M.
    [J]. CLINICAL OBSTETRICS AND GYNECOLOGY, 2013, 56 (01): : 44 - 50
  • [3] HPV mRNA testing in cervical cancer screening
    Arbyn, Marc
    Canfell, Karen
    Poljak, Mario
    Berkhof, Johannes
    de Sanjose, Silvia
    Wentzensen, Nicolas
    [J]. LANCET ONCOLOGY, 2022, 23 (10): : E437 - E437
  • [4] HPV testing for primary cervical cancer screening
    Ronco, Guglielmo
    Segnan, Nereo
    [J]. LANCET, 2007, 370 (9601): : 1740 - 1742
  • [5] HPV testing for cervical cancer screening in Croatia
    Grce, Magdalena
    Grahovac, Blazenka
    Rukavina, Tomislav
    Vrdoljak-Mozetic, Danijela
    Glavas-Obrovac, Ljubica
    Kaliterna, Vanja
    Zele-Starcevic, Lidija
    [J]. COLLEGIUM ANTROPOLOGICUM, 2007, 31 : 67 - 71
  • [6] HPV DNA testing for cervical cancer screening
    Wright, Thomas C., Jr.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2006, 95 : S239 - S246
  • [7] HPV testing for primary cervical cancer screening
    不详
    [J]. REPRODUCTIVE HEALTH MATTERS, 2008, 16 (32) : 194 - 195
  • [8] hrHPV DNA testing in cervical cancer screening. First round results From the HPV for CervicAL screening (HPV FOCAL) trial
    van Niekerk, D.
    Ogilvie, G.
    Krajden, M.
    Martin, R.
    Stuart, G.
    Ceballos, K.
    Peacock, S.
    Ehlen, T.
    Smith, L.
    Franco, E.
    Coldman, A.
    [J]. HISTOPATHOLOGY, 2012, 61 : 57 - 57
  • [9] Cervical cancer and human papillomavirus: South African guidelines for screening and testing
    Botha, Hennie
    Cooreman, Bruno
    Dreyer, Greta
    Lindeque, Gerhard
    Mouton, Arrie
    Guidozzi, Franco
    Koller, Tony
    Smith, Trudy
    Hoosen, Anwar
    Marcus, Louis
    Moodley, Manivasan
    Soeters, Robbie
    [J]. SOUTHERN AFRICAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2010, 2 (01) : 23 - 26
  • [10] Physician Adherence to HPV Co-Testing Guidelines for Cervical Cancer Screening
    Einck, Ashley
    Cansino, Catherine
    [J]. OBSTETRICS AND GYNECOLOGY, 2016, 127 : 57S - 57S